Rationale and design of Non-antithrombotic Therapy After Transcatheter Aortic Valve Implantation (NAPT) Trial

Inohara, Taku; Otsuka, Toshiaki; Watanabe, Yusuke; Shirai, Shinichi; Tada, Norio; Yamanaka, Futoshi; Ueno, Hiroshi; Ohno, Yohei; Tabata, Minoru; Suzuyama, Hiroto; Asami, Masahiko; Yamawaki, Masahiro; Izumo, Masaki; Yamasaki, Kazumasa; Nishina, Hidetaka; Fuku, Yasushi; Mizutani, Kazuki; Yashima, Fumiaki; Yamamoto, Masanori; Hayashida, Kentaro

doi:10.1016/j.cct.2023.107358

Cited by 2 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Acknowledging the important limitations given by the observational design, this study represents the first evidence for no-antithrombotic therapy after TAVI, which may turn useful, particularly in higher-risk patients. Further validation of these results through additional studies is essential to establish the reliability and generalizability of this strategy and will be evaluated in dedicated trials [67].…”

Section: No Antithrombotic Therapymentioning

confidence: 99%

Antithrombotic Therapy in Patients Undergoing Transcatheter Aortic Valve Implantation

Pallante,

Costa,

Garcia Ruiz

et al. 2024

Preprint

View full text Add to dashboard Cite

Transcatheter Aortic Valve Implantation (TAVI) now represents the mainstay in the treatment of severe aortic stenosis. Owing to its exceptional procedural efficacy and safety, TAVI has been extended to include patients at lower surgical risk, thus now encompassing a diverse patient population receiving this treatment. Yet, long-term outcomes also depend on optimal medical therapy for secondary vascular prevention, with antithrombotic therapy serving as a cornerstone. Leveraging data from multiple randomized controlled trials, current guidelines generally recommend single antithrombotic therapy, with either single antiplatelet therapy (SAPT) or oral anticoagulation (OAC) alone in those patients without, or with atrial fibrillation respectively. Yet, individualization of this pattern, as well as specific case uses, may be needed based on individual-patient characteristics and concurrent procedures. This review aims to discuss the evidence supporting antithrombotic treatments in patients treated with TAVI, indications for a standardized treatment, as well as specific considerations for an individualized approach to treatment.

show abstract

Section: No Antithrombotic Therapymentioning

confidence: 99%

Antithrombotic Therapy in Patients Undergoing Transcatheter Aortic Valve Implantation

Pallante,

Costa,

Garcia Ruiz

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Acknowledging the important limitations given by the observational design, this study represents the first evidence of no-antithrombotic therapy after TAVI, which may become useful, particularly for higher-risk patients. Further validation of these results through additional studies is essential to establish the reliability and generalizability of this strategy and will be evaluated in dedicated trials [67].…”

Section: No Antithrombotic Therapymentioning

confidence: 99%

“…This study will evaluate the onset of leaflet thrombosis with cardiac CT and transthoracic echocardiography at 3 months post-TAVI (NCT05493657). Finally, the NAPT trial [67] will recruit 360 patients undergoing TAVI who will be randomized to aspirin (75 mg to 100 mg) or no-antithrombotic treatment after the procedure. The study's primary outcome is a combination of death from any cause, heart attack, stroke, and bleeding.…”

Section: Future Perspective On Optimization Of Antithrombotic Therapy...mentioning

confidence: 99%

Antithrombotic Therapy in Patients Undergoing Transcatheter Aortic Valve Implantation

Pallante,

Costa,

Garcia Ruiz

et al. 2024

JCM

View full text Add to dashboard Cite

Transcatheter aortic valve implantation (TAVI) now represents the mainstay of treatment for severe aortic stenosis. Owing to its exceptional procedural efficacy and safety, TAVI has been extended to include patients at lower surgical risk, thus now encompassing a diverse patient population receiving this treatment. Yet, long-term outcomes also depend on optimal medical therapy for secondary vascular prevention, with antithrombotic therapy serving as the cornerstone. Leveraging data from multiple randomized controlled trials, the current guidelines generally recommend single antithrombotic therapy, with either single antiplatelet therapy (SAPT) or oral anticoagulation (OAC) alone in those patients without or with atrial fibrillation, respectively. Yet, individualization of this pattern, as well as specific case uses, may be needed based on individual patient characteristics and concurrent procedures. This review aims to discuss the evidence supporting antithrombotic treatments in patients treated with TAVI, indications for a standardized treatment, as well as specific considerations for an individualized approach to treatment.

show abstract

Rationale and design of Non-antithrombotic Therapy After Transcatheter Aortic Valve Implantation (NAPT) Trial

Cited by 2 publications

References 12 publications

Antithrombotic Therapy in Patients Undergoing Transcatheter Aortic Valve Implantation

Antithrombotic Therapy in Patients Undergoing Transcatheter Aortic Valve Implantation

Antithrombotic Therapy in Patients Undergoing Transcatheter Aortic Valve Implantation

Contact Info

Product

Resources

About